Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from

and

Download Data

Compass Therapeutics Inc. Selling, General, and Administrative Expenses (SG&A) 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -2.86%

Compass Therapeutics Inc. Selling, General, and Administrative Expenses (SG&A) 3 year CAGR is -2.86% for the Trailing 12 Months (TTM) ending March 31, 2024, a -206.15% change year over year. Selling, General, and Administrative Expenses (SG&A) consit of the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Compass Therapeutics Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 11.96 M, a 8.18% change year over year.
Compass Therapeutics Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 11.06 M, a -18.41% change year over year.
Compass Therapeutics Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 13.55 M, a 22.70% change year over year.
Compass Therapeutics Inc. Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 11.05 M.

NASDAQ: CMPX

Compass Therapeutics Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street, Boston, MA, United States, 02135
Employees	32
Sector	Healthcare
Industry	Biotechnology

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends